title: Assessing somatic hypermutation in Ramos B cells after overexpression or knockdown of specific genes.
abstract: B cells start their life with low affinity antibodies generated by V(D)J recombination. However, upon detecting a pathogen, the variable (V) region of an immunoglobulin (Ig) gene is mutated approximately 100,000-fold more than the rest of the genome through somatic hypermutation (SHM), resulting in high affinity antibodies. In addition, class switch recombination (CSR) produces antibodies with different effector functions depending on the kind of immune response that is needed for a particular pathogen. Both CSR and SHM are initiated by activation-induced cytidine deaminase (AID), which deaminates cytosine residues in DNA to produce uracils. These uracils are processed by error-prone forms of repair pathways, eventually leading to mutations and recombination. Our current understanding of the molecular details of SHM and CSR come from a combination of studies in mice, primary cells, cell lines, and cell-free experiments. Mouse models remain the gold standard with genetic knockouts showing critical roles for many repair factors (e.g. Ung, Msh2, Msh6, Exo1, and polymerase η). However, not all genes are amenable for knockout studies. For example, knockouts of several double-strand break repair proteins are embryonically lethal or impair B-cell development. Moreover, sometimes the specific function of a protein in SHM or CSR may be masked by more global defects caused by the knockout. In addition, since experiments in mice can be lengthy, altering expression of individual genes in cell lines has become an increasingly popular first step to identifying and characterizing candidate genes. Ramos - a Burkitt lymphoma cell line that constitutively undergoes SHM - has been a popular cell-line model to study SHM. One advantage of Ramos cells is that they have a built-in convenient semi-quantitative measure of SHM. Wild type cells express IgM and, as they pick up mutations, some of the mutations knock out IgM expression. Therefore, assaying IgM loss by fluorescence-activated cell scanning (FACS) provides a quick read-out for the level of SHM. A more quantitative measurement of SHM can be obtained by directly sequencing the antibody genes. Since Ramos cells are difficult to transfect, we produce stable derivatives that have increased or lowered expression of an individual gene by infecting cells with retroviral or lentiviral constructs that contain either an overexpression cassette or a short hairpin RNA (shRNA), respectively. Here, we describe how we infect Ramos cells and then use these cells to investigate the role of specific genes on SHM (Figure 1).
authors.affiliation: Department of Immunology, Duke University, USA.
authors.forename: Dana C
authors.initials: DC
authors.lastname: Upton
authors.forename: Shyam
authors.initials: S
authors.lastname: Unniraman
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology / Q000502:physiology*; D045744:Cell Line, Tumor; D015870:Gene Expression; D055785:Gene Knockdown Techniques / Q000379:methods*; D006801:Humans; D007075:Immunoglobulin M / Q000235:genetics / Q000276:immunology; D027041:Somatic Hypermutation, Immunoglobulin / Q000235:genetics* / Q000276:immunology
chemical_list: D007075:Immunoglobulin M
references.citation: Int Immunol. 2001 Sep;13(9):1175-84
references.pmid: 11526098
references.citation: Immunity. 1998 Jul;9(1):135-41
references.pmid: 9697843
references.citation: Nat Immunol. 2004 Feb;5(2):224-9
references.pmid: 14716311
references.citation: Annu Rev Immunol. 2008;26:481-511
references.pmid: 18304001
references.citation: Cell. 2011 Feb 4;144(3):353-63
references.pmid: 21255825
references.citation: J Immunol. 2008 Dec 1;181(11):7835-42
references.pmid: 19017973
references.citation: Curr Opin Immunol. 2006 Apr;18(2):164-74
references.pmid: 16464563
references.citation: Int Immunol. 1996 Feb;8(2):193-201
references.pmid: 8671604
references.citation: Eur J Immunol. 2008 Oct;38(10):2796-805
references.pmid: 18825746
references.citation: J Exp Med. 2004 Jul 5;200(1):61-8
references.pmid: 15238605
references.citation: Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7376-81
references.pmid: 10377422
references.citation: J Biol Chem. 1999 Jun 25;274(26):18470-6
references.pmid: 10373455
references.citation: J Virol. 1998 Nov;72(11):8463-71
references.pmid: 9765382
references.citation: Immunity. 1998 Dec;9(6):859-69
references.pmid: 9881976
references.citation: J Exp Med. 2007 Jan 22;204(1):17-23
references.pmid: 17190840
references.citation: Nat Biotechnol. 2002 Nov;20(11):1129-34
references.pmid: 12379869
references.citation: Nat Struct Mol Biol. 2011 Jan;18(1):75-9
references.pmid: 21131982
references.citation: Nat Immunol. 2005 Jul;6(7):730-6
references.pmid: 15937485
references.citation: Annu Rev Biochem. 2007;76:1-22
references.pmid: 17328676
references.citation: Nucleic Acids Res. 1997 Aug 1;25(15):2985-91
references.pmid: 9224597
references.citation: Nature. 2000 Nov 9;408(6809):216-21
references.pmid: 11089977
references.citation: Curr Biol. 2001 Jan 23;11(2):105-9
references.pmid: 11231126
references.citation: Curr Biol. 2002 Oct 15;12(20):1748-55
references.pmid: 12401169
references.citation: J Exp Med. 1998 Jun 1;187(11):1745-51
references.pmid: 9607916
references.citation: Mol Immunol. 2007 Jan;44(4):567-75
references.pmid: 16542725
references.citation: Mol Cell Biol. 1996 Dec;16(12):7133-43
references.pmid: 8943369
references.citation: Cell. 2010 Oct 1;143(1):122-33
references.pmid: 20887897